insights_auto
Prečo akcie LXRX klesli 2,84%?
Preskúmať podrobnejšiechevron_right
LXRX:NASDAQ
Lexicon Pharmaceuticals Inc
1,71 USD
arrow_downward
-2,84%(-0,050) 1 d.
9. 10., 14:13:12 GMT-4 · USD
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre LXRX…
Otvoriť
1,75 USD
Vysoká
1,77 USD
Nízka
1,70 USD
Trh. kap.
760,87 mil.
Priem. obj.
3,08 mil.
Objem
1,13 mil.
Max. za 52 týž.
2,68 USD
Min. za 52 týž.
1,10 USD
Výnosy na akciu
-0,15 USD
Beta
1,36
Akcie v obehu
444,96 mil.
Počet zamestnancov
81
Otvoriť
1,75 USD
Vysoká
1,77 USD
Nízka
1,70 USD
Trh. kap.
760,87 mil.
Priem. obj.
3,08 mil.
Objem
1,13 mil.
Max. za 52 týž.
2,68 USD
Min. za 52 týž.
1,10 USD
Výnosy na akciu
-0,15 USD
Beta
1,36
Akcie v obehu
444,96 mil.
Počet zamestnancov
81
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
MarketWatch
·
pred 10 minútami
Why you need to take a closer look at your favorite stock index
The Manila Times
·
pred 59 minútami
Terminal1, the operating system built for public companies, announced today that U.S Gold Corp (NASDAQ:USAU) has joined the Terminal1 platform
Simply Wall Street
·
pred 17 minútami
How Lower Borrowing Costs Will Impact Magnite Stock (MGNI)
Nasdaq
·
pred 4 hodinami
WISeSat.Space Holdings Corp. Rings the Opening Bell
Profil
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
Informácie o subjekte Lexicon Pharmaceuticals Inc
Generálny riaditeľLonnel Coats
Zamestnanci81
Dátum založenia1995
Hlavné sídlo-
Odvetvie-